Close

Horizon Pharma (HZNP) PT Lowered to $24 at BMO Capital on FA Miss; Maintains 'Outperform'

December 8, 2016 12:49 PM EST Send to a Friend
BMO Capital analyst Gary Nachman lowered his price target on Horizon Pharma (NASDAQ: HZNP) to $24.00 (from $29.00) but maintained ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login